Table 6. In Vitro Susceptibility Rates of different pathogens to empiric initial intraperitoneal therapies in period 3 (2004–2014).
| 2004–2014 | Cefazolinn n (% susceptible) | Ceftazidimn n (% susceptible) | Gentamicin n (% susceptible) | Vancomycin n (% susceptible) |
|---|---|---|---|---|
| Gram-positive organisms | 113 (58) | 5 (100) a | 130 (71) | 156 (98) b |
| Staphylococcus aureus | 17 (88) | NT | 17 (88) | 17 (100) |
| MSSA | 15 (100) | NT | 15 (94) | 15 (100) |
| MRSA | 2 (0) | NT | 2 (50) | 2 (100) |
| CNS | 73 (38) | NT | 73 (70) | 70 (100) |
| MRSE | NT | NT | 45 (56) | 45 (100) |
| Enterococcus spp. | NT | NT | 16 (53) | 16 (81) b |
| Streptococcus spp. | 19 (95) | NT | 10 (40) | 39 (100) |
| Other gram positive rods | 2 (0) | 2 (100) a | 10 (70) | 10 (100) |
| Others | 1 (100) | 3 (100) a | 3 (100) | 4 (100) |
| Gram-negative organisms | NT | 68 (93) | 68 (90) | NT |
| Pseudomonas spp. | NT | 10 (100) | 10 (90) | NT |
| Stenotrophomonas spp. | NT | 1 (100) | 1 (100) | NT |
| Escherichia coli | NT | 31 (94) | 31 (94) c | NT |
| Klebsiella spp. | NT | 9 (78) c | 9 (89) | NT |
| Acinetobacter spp. | NT | 3 (33) | 3 (100) | NT |
| Others | NT | 14 (93) | 14 (71) | NT |
MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; CNS, coagulase-negative staphylococci; MRSE, methicillin-resistant Staphylococcus epidermidis; NA, not available; NT, not tested;
a Gemella morbillorum, Micrococcus luteus
bVancomycin resistant enterococcius (VRE);
cthird generation cephalosporin resistant gram-negative rods (3GCR-GN); variables are expressed in number of antibiograms (percentage in parentheses regarding Susceptibility Rate);